Psilocybin and Depression: What Brain Research Has Found

Most news about psilocybin and depression asks whether it works. Researchers are just as interested in a second question: if it helps, how? A single dose leaves the body within a day, yet in clinical trials some people's depression scores stayed lower for weeks or months. Something has to explain that gap. This guide walks through the main ideas scientists are testing, the studies behind each one, and the honest limits of what we know.

A quick note first. Everything below comes from controlled research: measured doses of pure psilocybin, carefully screened volunteers or patients, and trained staff in the room. None of it is medical advice, and none of it shows that mushrooms taken at home treat depression. For the trial results themselves, see our posts on the clinical research up to 2022 and the 2026 depression trials.

Step one: the serotonin 2A receptor

When you swallow psilocybin, your body converts it into psilocin, the compound that actually acts on the brain. Psilocin mainly switches on one type of serotonin receptor, called 5-HT2A. These receptors are especially dense in the brain's outer layers, in areas involved in thinking about ourselves, imagining and making sense of experience.

A Danish brain imaging study of eight volunteers measured how many of these receptors psilocin occupied and found that the more receptors were occupied, the stronger the psychedelic effects people reported. That is why researchers treat the 5-HT2A receptor as the front door for psilocybin's effects. What happens after the door opens is where the theories begin.

Idea one: loosening the brain's usual patterns

The brain is organized into networks of regions that tend to work together. One of them, the default mode network, is most active when the mind wanders, thinks about the self, replays the past or worries about the future. Some researchers suggest that in depression this network can get stuck in rigid, repetitive loops, the kind of thinking people describe as rumination.

• In 2012, a team at Imperial College London scanned 30 healthy volunteers as psilocybin took effect. They saw drops in activity and blood flow in key hub regions, including core parts of the default mode network, and the size of the drop in one of these areas tracked how intense the experience felt.
• In 2024, researchers at Washington University in St. Louis scanned seven healthy adults many times before, during and after a dose, and published the results in Nature. Psilocybin disrupted the brain's normal network patterns more than three times as much as a stimulant used for comparison, with the biggest change in the default mode network. Most of this returned to normal once the drug wore off, but one change, a weaker link between the default mode network and part of the hippocampus, lasted for weeks.
• In 2022, the Imperial team published brain scans from two of its depression trials in Nature Medicine. After psilocybin therapy, patients' brain networks were less walled off from each other, which the authors called greater global integration, and this change tracked how much people improved. Patients who took the antidepressant escitalopram in the same trial did not show a comparable change.

Together these studies paint a picture of psilocybin temporarily shaking up rigid patterns, after which the brain may settle into a more flexible arrangement. It is an appealing idea. It also rests on small groups of people, and a link between a brain change and an improvement does not prove that one caused the other.

Idea two: new connections between brain cells

In animal studies, depression and chronic stress are linked with the loss of dendritic spines, the tiny branches nerve cells use to connect with each other. Several labs have tested whether psychedelics reverse this.

• A 2018 study in Cell Reports found that several psychedelics made nerve cells grow more branches and connections, in cell cultures and in animals. Scientists call this neuroplasticity.
• A 2021 study in Neuron imaged the brains of living mice and found that one dose of psilocybin increased the size and number of dendritic spines in the frontal cortex by about 10 per cent within 24 hours. The changes were still there a month later in the mice that were followed up.
• A 2023 study in Nature Neuroscience reported that psilocin and LSD bind directly to TrkB, the receptor for a growth factor called BDNF that helps the brain adapt, and that in mice this, rather than the 5-HT2A receptor, drove the antidepressant-like effects. This finding is still debated and needs to be confirmed by other labs.

Animal and cell studies are useful because they let scientists watch single connections, which is impossible in people. But a mouse is not a person with depression, and these results show what may be happening, not what definitely happens in humans.

Idea three: the experience itself

There is a third explanation, and it is the one trial participants tend to describe: the experience matters. In a small 2018 Imperial study of 20 people with treatment-resistant depression, those who reported a stronger sense of "oceanic boundlessness", a feeling of unity and blissful connection, had better depression scores five weeks later. Several other studies, including the cancer distress trials, have found that the intensity of mystical-type experiences predicted better outcomes.

Not everyone agrees on what that means. In 2021, two papers in the same journal laid out both sides. Johns Hopkins researchers David Yaden and Roland Griffiths argued that the subjective experience is necessary for lasting benefits. Neuroscientist David Olson argued that it may not be, pointing out that the evidence is largely correlational and that plasticity effects appear in animals that cannot report a mystical experience. Companies are now developing compounds that aim to promote plasticity without a trip, and how those perform should help settle the question.

So which one is right?

Probably some of each, working together. A widely discussed working model goes like this: psilocybin acts on 5-HT2A receptors, which briefly loosens rigid patterns of brain activity and thought, opens a window of greater plasticity, and gives people an intense experience that, with good preparation and support, can help them see their lives differently. Each link in that chain has some evidence behind it, and none of them is proven.

What this does not mean

• It does not mean psilocybin "rewires" the brain in a guaranteed or permanent way. Results in trials varied a lot between people, and for some the benefit faded.
• It does not mean more is better. The trials used one or two measured doses with weeks of preparation and follow-up.
• It does not mean a trip on its own is therapy. Every study above that involved patients paired psilocybin with professional psychological support.
• It does not mean mushrooms are safe for everyone. Trials exclude people with a personal or family history of psychosis or bipolar disorder, some heart conditions and certain medications. Our guide to psilocybin and medications covers the interactions to know.

If you're struggling

Depression is serious and treatable. Talk to your doctor about your options, including clinical trials. In Canada, legal access to psilocybin for a medical need runs through Health Canada's Special Access Program or an authorized trial, as our Canada guide explains. If you are thinking about suicide or are in crisis, call or text 9-8-8 at any time, or call 911.

Sources

• Madsen et al. (2019), Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels, Neuropsychopharmacology
• Carhart-Harris et al. (2012), Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin, PNAS
• Siegel et al. (2024), Psilocybin desynchronizes the human brain, Nature
• Daws et al. (2022), Increased global integration in the brain after psilocybin therapy for depression, Nature Medicine
• Ly et al. (2018), Psychedelics promote structural and functional neural plasticity, Cell Reports
• Shao et al. (2021), Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo, Neuron
• Moliner et al. (2023), Psychedelics promote plasticity by directly binding to BDNF receptor TrkB, Nature Neuroscience
• Roseman, Nutt and Carhart-Harris (2018), Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression, Frontiers in Pharmacology
• Yaden and Griffiths (2021), The subjective effects of psychedelics are necessary for their enduring therapeutic effects, ACS Pharmacology & Translational Science
• Olson (2021), The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects, ACS Pharmacology & Translational Science

This guide is general information, not medical or legal advice. If you have health questions, talk to a health professional.